AtorvaStatin Postpartum and Reduction of Cardiovascular risK

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2024
The objective is to conduct a double-blinded randomized controlled trial of atorvastatin vs. placebo among postpartum individuals with hypertensive disorders of pregnancy, to improve cardiovascular risk score postpartum. For this, 76 individuals with hypertensive disorders of pregnancy (HDP) will be randomized to atorvastatin 10mg or placebo, which will be started in the postpartum period after cessation of breast feeding and continued for 3 months.
Epistemonikos ID: 56e947369dfeb1707be19dc82f62c321eed72869
First added on: Apr 17, 2025